AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Netherlands [legacy through FY19] by Year
Netherlands [legacy through FY19] ($M) ($M)
AbbVie Netherlands [legacy through FY19]: $163M in FY2019, down 53.7% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2019
163
Period ended Dec 31, 2019
Change on a year earlier
-53.7%
352 in FY2018
History
5 years
Since FY2015
Sources
3
Documents cited below
Where the FY2019 figure comes from
Source: Form 10-K (filed 2020-02-21) ↗
Reported in Form 10-K Segment & Geographic Information.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Netherlands [legacy through FY19] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 163 | -53.7% | Form 10-K (filed 2020-02-21) ↗ |
| FY2018 | Dec 31, 2018 | 352 | -2.8% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 362 | +2.8% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 352 | +5.4% | Form 10-K (filed 2019-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 334 | – | Form 10-K (filed 2018-02-16) ↗ |
Cite this data
StockData. (2026). AbbVie Netherlands [legacy through FY19] ($M), annual FY2015–FY2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/geo-rev-nl-leg
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.